Compare XMTR & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XMTR | GENB |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2021 | N/A |
| Metric | XMTR | GENB |
|---|---|---|
| Price | $39.96 | $11.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $58.60 | $25.00 |
| AVG Volume (30 Days) | ★ 814.2K | 364.6K |
| Earning Date | 05-05-2026 | 05-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $18.38 | $45.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $20.95 | $11.00 |
| 52 Week High | $73.87 | $14.21 |
| Indicator | XMTR | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 44.08 |
| Support Level | $39.50 | $11.21 |
| Resistance Level | $42.98 | $13.69 |
| Average True Range (ATR) | 2.59 | 1.12 |
| MACD | 0.67 | -0.10 |
| Stochastic Oscillator | 30.94 | 9.65 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.